Related references
Note: Only part of the references are listed.Theranostic Nanoparticles with Controlled Release of Gemcitabine for Targeted Therapy and MRI of Pancreatic Cancer
Gee Young Lee et al.
ACS NANO (2013)
Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
Uma Prabhakar et al.
CANCER RESEARCH (2013)
HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas
Federica Guzzo et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2012)
In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles
Jaehong Key et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Potential of PET to Predict the Response to Trastuzumab Treatment in an ErbB2-Positive Human Xenograft Tumor Model
Gabriela Kramer-Marek et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging
Boguslaw Tomanek et al.
NEURO-ONCOLOGY (2012)
Affibody-DyLight Conjugates for In Vivo Assessment of HER2 Expression by Near-Infrared Optical Imaging
Rafal Zielinski et al.
PLOS ONE (2012)
Affibody-based nanoprobes for HER2-expressing cell and tumor imaging
Jinhao Gao et al.
BIOMATERIALS (2011)
T-1-Weighted Ultrashort Echo Time Method for Positive Contrast Imaging of Magnetic Nanoparticles and Cancer Cells Bound With the Targeted Nanoparticles
Longjiang Zhang et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2011)
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results
Gooitzen M. van Dam et al.
NATURE MEDICINE (2011)
Rethinking ovarian cancer: recommendations for improving outcomes
Sebastian Vaughan et al.
NATURE REVIEWS CANCER (2011)
PET/NIRF/MRI triple functional iron oxide nanoparticles
Jin Xie et al.
BIOMATERIALS (2010)
Near IR Heptamethine Cyanine Dye-Mediated Cancer Imaging
Xiaojian Yang et al.
CLINICAL CANCER RESEARCH (2010)
Near-infrared fluorescence: application to in vivo molecular imaging
Scott A. Hilderbrand et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice
A. Cirstoiu-Hapca et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules
Richard P. Baum et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer
Raquel De Souza et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles
Kenneth E. Scarberry et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2010)
Imaging ovarian cancer and peritoneal metastases-current and emerging techniques
Stavroula Kyriazi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Delivering nanomedicine to solid tumors
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting
Kai Chen et al.
BIOMATERIALS (2009)
Receptor-Targeted Nanoparticles for In vivo Imaging of Breast Cancer
Lily Yang et al.
CLINICAL CANCER RESEARCH (2009)
Molecular Imaging of Pancreatic Cancer in an Animal Model Using Targeted Multifunctional Nanoparticles
Lily Yang et al.
GASTROENTEROLOGY (2009)
On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model
Anna Orlova et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Mediating Tumor Targeting Efficiency of Nanoparticles Through Design
Steven D. Perrault et al.
NANO LETTERS (2009)
The biology of ovarian cancer: new opportunities for translation
Robert C. Bast et al.
NATURE REVIEWS CANCER (2009)
HER-2-Targeted Nanoparticle-Affibody Bioconjugates for Cancer Therapy
Frank Alexis et al.
CHEMMEDCHEM (2008)
Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging
Sang Bong Lee et al.
CLINICAL CANCER RESEARCH (2008)
Does a targeting ligand influence nanoparticle tumor localization or uptake?
Kathleen F. Pirollo et al.
TRENDS IN BIOTECHNOLOGY (2008)
HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
Marianne Tuefferd et al.
PLOS ONE (2007)
Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging
Jae-Hyun Lee et al.
NATURE MEDICINE (2007)
Synthetic affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors
Anna Orlova et al.
CANCER RESEARCH (2007)
Clinical activity of Pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status
Michael S. Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
In vivo imaging of tumor response to therapy using a dual-modality imaging strategy
Z Medarova et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Tumor Imaging using a picomolar affinity HER2 binding affibody molecule
A Orlova et al.
CANCER RESEARCH (2006)
Nanoparticle imaging of integrins on tumor cells
Xavier Montet et al.
NEOPLASIA (2006)
EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma
CA Livasy et al.
GYNECOLOGIC ONCOLOGY (2006)
Ovarian cancer metastasis: Integrating insights from disparate model organisms
H Naora et al.
NATURE REVIEWS CANCER (2005)
A dual fluorochrome probe for imaging proteases
MF Kircher et al.
BIOCONJUGATE CHEMISTRY (2004)
HER2 expression in cervical cancer as a potential therapeutic target -: art. no. 59
A Chavez-Blanco et al.
BMC CANCER (2004)
Cancer of the ovary
SA Cannistra
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Secondary surgical cytoreduction for advanced ovarian carcinoma
PG Rose et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Synthesis of monodisperse iron oxide nanocrystals by thermal decomposition of iron carboxylate salts
WW Yu et al.
CHEMICAL COMMUNICATIONS (2004)
Ovarian cancer: Strategies for overcoming resistance to chemotherapy
R Agarwal et al.
NATURE REVIEWS CANCER (2003)
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
MG Harisinghani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Shedding light onto live molecular targets
Ralph Weissleder et al.
NATURE MEDICINE (2003)
Ovarian cancer: progress and continuing controversies in management
C Moss et al.
EUROPEAN JOURNAL OF CANCER (2002)
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
RE Bristow et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
